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Sensing of nutrients by chemosensory cells in the gastrointestinal tract plays a key role in
transmitting food-related signals, linking information about the composition of ingested
foods to digestive processes. In recent years, a number of G protein-coupled receptors
(GPCR) responsive to a range of nutrients have been identified. Many are localised to intes-
tinal enteroendocrine (chemosensory) cells, promoting hormonal and neuronal signalling
locally, centrally and to the periphery. The field of gut sensory systems is relatively new
and still evolving. Despite huge interest in these nutrient-sensing GPCR, both as sensors
for nutritional status and targets for preventing the development of metabolic diseases,
major challenges remain to be resolved. However, the gut expressed sweet taste receptor,
resident in L-enteroendocrine cells and responsive to dietary sweetener additives, has already
been successfully explored and utilised as a therapeutic target, treating weaning-related dis-
orders in young animals. In addition to sensing nutrients, many GPCR are targets for drugs
used in clinical practice. As such these receptors, in particular those expressed in L-cells, are
currently being assessed as potential new pathways for treating diabetes and obesity.
Furthermore, growing recognition of gut chemosensing of microbial-produced SCFA
acids has led further attention to the association between nutrition and development of
chronic disorders focusing on the relationship between nutrients, gut microbiota and health.
The central importance of gut nutrient sensing in the control of gastrointestinal physiology,
health promotion and gut–brain communication offers promise that further therapeutic suc-
cesses and nutritional recommendations will arise from research in this area.
Nutrient sensing: Enteroendocrine cell: G protein-coupled receptors
The intestinal epithelium is a major boundary with the
outside world. Epithelial cells lining the surface of the
intestinal epithelium are in direct contact with a luminal
environment, the composition of which varies dramatically.
It has long been recognised that the gut is capable of sens-
ing changes in its luminal content and responding by releas-
ing chemical signals. In 1902, Bayliss and Starling(1) noted
that increasing the acidity in the lumen of the small intes-
tine elicited pancreatic secretions, and that this was
mediated, not via the nervous system, but by a humoral
factor produced by the gut epithelium that they termed
secretin.
Indeed, we now know that the nerve endings that
transmit signals evoked by changes in the gut luminal
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contents do not reach the intestinal lumen and that infor-
mation about the chemical nature of the luminal contents
is transmitted to neurons via enteroendocrine cells (EEC)
linking the gut, brain and peripheral tissues.
EEC, scattered amongst the cells lining the intestinal
epithelium, are pivotal to the chemosensing pathways
of the intestinal tract. They are flask-shaped, with the
majority having open-type morphology with apically
extended processes making direct contact with ingested
nutrients and microbial products in the gut lumen.
These cells respond to changes in luminal contents by
releasing gut hormones into systemic circulation via
their basolateral membrane domain. There are at least
sixteen discrete cell types that make up the enteroendo-
crine family (generally named after letters of alphabet)
and collectively they produce over twenty different hor-
mones(2). These include cholecystokinin (CCK), peptide
YY (PYY) and glucagon-like peptides 1 and 2 (GLP-1,
GLP-2). CCK is released by I-cells predominantly
located in the proximal intestine, whereas PYY, GLP-1
and GLP-2 are secreted mostly by L-cells residing fre-
quently in the distal gut. However, L-cells have also
been identified in the duodenum albeit in lower number
than observed in jejunum and ileum(3). Secretion of
CCK, GLP-1 or PYY slows down gastric emptying, as
well as reducing appetite and food intake. GLP-1 also
functions as an incretin hormone, stimulating insulin
secretion from pancreatic β-cells, improving meal-related
glycaemia. GLP-2, coproduced with GLP-1, promotes
intestinal epithelial cell growth and increased nutrient
absorption(4,5).
Although it was believed that gut hormone secretion
was the result of direct EEC sensing of nutrients in the
lumen of the intestine, until recently little was known
about the initial molecular recognition events involved
in the enteroendocrine luminal sensing.
G protein-coupled receptors and intestinal nutrient
sensing
G protein-coupled receptors (GPCR) represent the lar-
gest family of cell-surface mediators of signal transduc-
tion(6). They are encoded by about 800 different genes
in human subjects(7), enabling cells to respond to many
diverse sensory inputs. Hence, GPCR are well-
established targets for almost half of all therapeutic
drugs, yet many are denominated as ‘orphan receptors’
whose physiological agonists remain unknown. As such
these receptors have attracted significant attention in
terms of continued identification and characterisation,
with the recognition that they are potential targets for
novel drug discovery. With more recent evidence that
nutrient sensing in the gastrointestinal (GI) tract is
accomplished by a number of GPCR(8), the role of
these receptors as important nutritional targets is becom-
ing increasingly evident.
Nutrient-sensing GPCR are categorised as either class
A or class C. GPCR belonging to class C, such as the
calcium-sensing receptor (CaSR) and the taste 1 family
receptors (T1R) comprise an N-terminal signal sequence,
seven transmembrane domains coupled with a large
extracellular domain (Venus flytrap module) and
C-terminal cytoplasmic domain. Class A receptors such
as fatty acid receptors also have seven transmembrane
domains, but lack the Venus flytrap module(9). In gen-
eral, nutrient-sensing GPCR are classified based on
their α-subunits and the corresponding downstream sig-
nalling pathways they recruit. They are grouped into
families Gαs, Gαi, Gαq, Gα12/13, and gustducin. The
physiological effects produced by these receptors in
response to nutrients are mainly mediated via cyclic
adenosine monophosphate (cAMP) and Ca2+ signalling
cascades. Gαs stimulates adenylate cyclase leading to an
increase in intracellular concentration of cAMP. Gαi inhi-
bits adenylate cyclase resulting in decreased intracellular
cAMP. Gαq stimulates phospholipase C resulting in the
generation of diacylglycerol and inositol triphosphate,
which respectively activate protein kinase C triggering
Ca2+ release from intracellular stores. Gα12/13 couples to
the activation of the small G-protein Rho. Gustducin, a
heterotrimeric G protein and mainly a member of Gαi fam-
ily, can stimulate phosphodiesterase resulting in cAMP
degradation, but in parallel the co-released Gβγ subunits
activate phospholipase C-β2 leading to inositol
triphosphate-mediated Ca2+ release. The consequent eleva-
tion of cytoplasmic Ca2+ activates the Ca2+sensitive transi-
ent receptor potential channel M5 triggering membrane
depolarisation and opening of voltage-gated Ca2+ chan-
nels(9,10). It has also been reported that gustducin activa-
tion stimulates adenylate cyclase, increasing cAMP
directly or indirectly closing basolateral K+ channels and
triggering membrane depolarisation(11).
Several nutrient-sensing GPCR have been identified in
the intestinal epithelium. They are expressed mainly on
the apical membrane domain of EEC and are directly
activated by a variety of nutrients. These include recep-
tors for glucose, amino acids, peptides, protein hydroly-
sates, calcium and both long-chain fatty acids and
SCFA (Fig. 1)(12). Nutrient sensing initiates a cascade
of events involving hormonal and neural pathways.
This culminates in functional responses that ultimately
regulate vital physiological processes including food
intake (appetite and satiety), nutrient digestion and
absorption, intestinal barrier function, gut motility, and
insulin secretion.
This review focuses on GPCR responsive to digestive
products of macronutrients.
Carbohydrates
One of the primary functions of carbohydrates is to pro-
vide body energy. They comprise sugars, digestible poly-
saccharides (such as starch) and non-digestible
carbohydrates consisting of plant-based fibres and non-
starch polysaccharides. In the small intestine, digestible
polysaccharides are hydrolysed by pancreatic amylase
and brush border membrane disaccharidases to constitu-
ent monosaccharides, glucose, galactose and fructose(13).
Non-digestible carbohydrates, which escape digestion in
the small intestine, reach the large intestine where they
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are fermented by gut microbiota, predominantly to
SCFA.
Intestinal glucose (sweet) sensing
Glucose is an effective inducer of secretion of gut hor-
mones such as GLP-1, GLP-2 and glucose-dependent
insulinotropic peptide (GIP). It has been shown that
there is a much greater insulin secretion from the pancreas
after orally-ingested glucose than from intravenous injec-
tion of the same amount of glucose (the incretin effect)(14),
inferring the presence of an intestinal luminal glucose
sensor responsible for glucose-induced gut peptide release.
In 2005, we reported, for the first time, that the heterodi-
meric sweet taste receptor T1R2-T1R3, previously charac-
terised in the lingual epithelium, is expressed in gut EEC,
and proposed that it acts as the intestinal glucose sensor(15).
Further work demonstrated that all signalling ele-
ments involved in sweet taste transduction in the gusta-
tory buds of the tongue, T1R2-T1R3, phospholipase
C-β2, transient receptor potential channel M5,
α-gustducin and other associated signalling elements,
are co-expressed in both L- and K-EEC in human and
mouse intestine(16,17). In mice in which the genes encod-
ing for α-gustducin and T1R3 were deleted, there was a
failure to secrete GLP-1 in response to luminal glu-
cose(16,17). These knockout mice also had abnormal insu-
lin response and prolonged elevation of postprandial
blood glucose, indicating that the sweet receptor
expressed in intestinal L-cells coupled to α-gustducin
sense luminal glucose leading to the secretion of
GLP-1(16,18). More recent work(19) has confirmed and
extended these studies to demonstrate that in mouse
small intestine, T1R2, T1R3, α-gustducin and GLP-2
are co-expressed in the same L-EEC and that mouse
intestine secretes GLP-2 in response to glucose(19).
Moreover, this glucose-induced GLP-2 release was inhib-
ited by gurmarin (a specific inhibitor of mouse
T1R3)(20,21). Furthermore, the non-nutritive sweetener,
sucralose, also induced GLP-2 release from mouse
Fig. 1. A schematic diagram of an enteroendocrine cell with luminal-nutrient sensing G
protein-coupled receptors (GPR) and downstream signalling pathways. Taken from Reimann et
al. (2012) with permission from Cell Press. CaSR, calcium-sensing receptor; FFAR, free fatty
acid receptor; TGR, G-protein-coupled bile acid receptor, GPBAR1; T1R, taste 1 receptor;
PLC, phospholipase C; AC, adenylate cyclase; TRPM5, transient receptor potential cation
channel subfamily M member 5; IP, inositol phosphate; PKC, protein kinase C; Epac2,
exchange protein directly activated by cAMP 2; PKA, Protein kinase A.
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small intestine, which was again inhibited by gurmarin.
However, the sweetener aspartame, which does not acti-
vate mouse T1R2-T1R3(22), did not induce GLP-2 release,
supporting the conclusion that the T1R2-T1R3 receptor,
expressed in L-cells, senses luminal glucose and sweeteners
to secrete GLP-2. A number of studies(3,23,24) confirming
the findings of previous reports(16,17) have demonstrated
that transcripts for T1R2, T1R3, α-gustducin, transient
receptor potential channel M5 and GLP-1 are expressed
in the mucosa of the human proximal intestine. Young
et al.(23) also reported that the expression of T1R2, at
mRNA level, was reduced in the intestine of diabetic sub-
jects with higher fasting blood glucose concentration(23).
The magnitude of GLP-1, GLP-2 and GIP secretion has
been reported to be diminished in patients with type 2 dia-
betes(25). A recent study has also shown that the number of
EEC, including L-cells, is reduced significantly in the intes-
tine of morbidly obese and diabetic individuals with type 2
diabetes compared to that in healthy controls(4). Thus, the
reduction in T1R2 transcript level observed in diabetics(23)
may be due to a reduced number of EEC expressing T1R2
and other signalling elements required for glucose-induced
GLP-1 secretion. Moreover, it has been demonstrated that
the intragastric administration of glucose, in healthy sub-
jects, resulted in the secretion of GLP-1 and PYY, which
was significantly reduced when lactisole, the specific inhibi-
tor of human T1R3(26) was co-administered(3,24). They
have concluded that in the human intestine, T1R2-T1R3
is involved in glucose-induced secretion of GLP-1 and
PYY, with potential consequences for reducing food
intake, decreasing gut motility and increasing insulin secre-
tion (the latter in response to GLP-1).
Mechanisms underlying intestinal sweet sensing and
glucose transport regulation
One important manifestation of intestinal glucose sens-
ing by T1R2-T1R3, expressed in L-cells, is the regulation
of intestinal glucose transport.
The major route for transport of dietary glucose from
the lumen of the intestine into absorptive enterocytes is
via the brush border membrane protein, the sodium glu-
cose co-transporter isoform 1 (SGLT1)(27,28). Absorption
of glucose by SGLT1 also activates electrolyte (NaCl)
and water absorption, the route used for oral rehydration
therapy(29–31). SGLT1 activity and expression have been
shown to be directly regulated by luminal glucose, including
metabolisable, non-metabolisable and membrane-imperme-
able glucose analogues(32–34). Furthermore, the pathway
underlying monosaccharide-enhanced SGLT1 expression
was via a luminal membrane glucose GPCR(34,35).
Recent experimental evidence has demonstrated that
T1R2-T1R3 expressed in L-cells senses dietary glucose
(and other natural/artificial sweeteners) resulting in the
secretion of GLP-2, which then, via a neuro-paracrine
pathway involving the enteric nervous system, enhances
the half-life of SGLT1 mRNA in neighbouring absorp-
tive enterocytes. This leads to increased activity and
expression of SGLT1, and enhanced intestinal glucose
absorption(19). Knocking out the genes for T1R2, T1R3
or GLP-2 receptor abolishes the ability of mouse intes-
tine to up-regulate SGLT1 expression and activity in
response to luminal glucose or sweeteners(17,19).
It has been shown that the expression (and activity) of
SGLT1 is enhanced in the intestine of human subjects
with type 2 diabetes. This increase was shown to be inde-
pendent of dietary carbohydrate intake level, or any
changes in blood glucose or insulin concentration(27),
and proposed to be due to alterations in the mechanisms
and signalling pathways involved in the regulation of
SGLT1 activity and expression.
As noted earlier, the total number of EEC, the expres-
sion of T1R2 and levels of gut hormones including
GLP-1, GLP-2 and GIP are all significantly reduced in
the intestine of diabetic individuals(4,23,25). Thus, it
appears that in type 2 diabetes, deregulation of intestinal
glucose sensing and downstream signalling may play a
role in the observed overexpression of intestinal SGLT1.
Therapeutic potential of taste 1 receptor 2 and receptor 3
Post weaning intestinal disorders are major health pro-
blems for the young. Weaning-associated diarrhoea,
dehydration and nutrient malabsorption result in high
levels of mortality in farm animals worldwide. The
finding that small concentrations of specific natural/artifi-
cial sweeteners are detected by the intestinal T1R2-T1R3
sweet receptor, activating the pathway leading to
increased glucose, electrolyte and water absorption
(oral rehydration therapy)(29), has attracted worldwide
uptake of these additive sweeteners in the diet of weaning
animals. This innovation has improved the health and
survival rate of young animals through avoidance of
intestinal disorders, thereby increasing weight, enhancing
immunity and optimising feed utilisation allowing the
translation of scientific discoveries to animal health and
welfare benefits(31,36,37). Modulation of human intestinal
T1R2-T1R3 activity may also have applications in
human subjects by controlling glucose absorption(23).
Proteins
Dietary proteins are essential for growth, provision of
energy and health maintenance. In the small intestine,
proteins are digested by pancreatic and brush border
membrane proteases to di-tri-oligopeptides and amino
acids. There are these products that likely target EEC
stimulating secretion of a range of gut hormones includ-
ing CCK, GLP-1 and PYY(38). The satiety effects asso-
ciated with high-protein diets can also be mediated by
sensing of the amino acid constituents of proteins.
Intestinal sensing of protein hydrolysis products
Amino acid sensing
A number of GPCR have been identified to respond to
amino acids. They belong to a sub-group of C class
GPCR and include CaSR, the heterodimeric umami
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receptor T1R1-T1R3, the goldfish 5⋅24 receptor and its
mammalian orthologue GPCR6A, and the metabotropic
glutamate receptors.
CaSR is a homodimeric receptor that predominantly
couples to Gαq, activating phosphatidylinositol-specific
phospholipase C and inducing mobilisation of intracellu-
lar Ca2+(39). However, it also couples to Gαs, Gαi and
Gα12/13
(40) . CaSR is a multimodal sensor for several key
nutrients, notably Ca2+ ions and L-amino acids, and is
expressed abundantly throughout the GI tract(39,41).
Although it acts as a sensor for Ca2+ in the gut lumen,
it is allosterically activated by L-amino acids; responding
to aromatic, aliphatic and polar, but not to branched or
positively charged, amino acids(42). CaSR is highly
expressed in gastrin-secreting G-, somatostatin-secreting
D-(43) and CCK-secreting I-cells(44), and has been pro-
posed to facilitate amino acid-induced secretion of
these gut hormones. In studies using secretin tumour
cell line (STC)-1 cells, it was shown that extracellular
presence of L-phenylalanine induced mobilisation of
intracellular Ca2+ and CCK secretion which was inhib-
ited with the allosteric CaSR inhibitor NPS2143(45).
Moreover, native intestinal I-cells from mice deficient
in CaSR showed impaired L-phenylalanine mediated
Ca2+ responses and CCK release(44), indicating that
CaSR plays a significant role in the chemosensing of
amino acids in the GI tract.
GPRC6A is a Gq/11-coupled receptor widely expressed
in human and rodent tissues. Being a promiscuous amino
acid sensor, and expressed in the digestive system, it
has been proposed to act as a candidate for sensing
digested amino acids in the GI tract(43,46). It has been
reported by two groups that GPRC6A is involved in
L-ornithine-induced GLP-1 release in the intestinal
L-cell line GLUTag(47,48). However, Oya et al.(48) were
unable to measure L-ornithine-induced GLP-1 release
from mixed primary cultures of mouse small intestine(48).
There are equally conflicting results using GPRC6A
knockout mouse models. Alamshah et al.(49) demon-
strated that L-arginine induced secretion of PYY from
both wild-type and GPRC6A KO mouse primary
colonic L-cells(49). Jørgensen & Bräuner-Osborne(50)
addressing the in vivo relevance of these findings, admi-
nistered L-ornithine and L-arginine orally to the full
locus and exon VI GPRC6A KO mouse models(50).
Whilst there was an immediate GLP-1 release that dimin-
ished over time, there were no overall differences in the
ability of KO-mouse models and wild-type mice to
secrete GLP-1 in response to these amino acids. The
authors concluded that GPRC6A, in vivo, does not
play a role in GLP-1 secretion in response to basic
L-amino acids(50). Further work is required to unravel
the precise role of GPRC6A in intestinal chemosensing.
Taste 1 receptor 1 and receptor 3
In taste cells of lingual epithelium, the heterodimeric
combination of T1R1 and T1R3, members of the T1R
family, has been identified as a broad-spectrum
L-amino acid sensor responsible for mediating perception
of the savoury umami taste of monosodium
glutamate(22,51). In rodents and many other mammalian
species, T1R1-T1R3 responds to a wide variety of
L-amino acids in the millimolar range. However, the
receptor is not activated by L-tryptophan(10). The
human T1R1-T1R3 complex functions as a much more
specific receptor, responding selectively to monosodium
glutamate and aspartic acid (as well as to the glutamate
analogue l-AP4)(22,51,52). The T1R1-T1R3 heterodimer,
such as the sweet receptor T1R2-T1R3, is expressed in
EEC(15) and is coupled to gustducin for the transmission
of intracellular signals(53). Using STC-1 cells and native
mouse intestinal tissue, it has been shown that gut
expressed T1R1-T1R3 serves as an intestinal L-amino
acid sensor modulating amino acid-induced CCK
release(54). Using siRNA to inhibit the expression of
T1R1 mRNA and protein in STC-1 cells, it was demon-
strated that the inhibition of T1R1 expression had no
effect on protein hydrolysate or peptide-induced CCK
release, indicating that T1R1-T1R3 is not the intestinal
sensor for peptones. However, in T1R1 knockdown
STC-1 cells, there was a significant decline in
phenylalanine-, leucine- and glutamate-induced CCK
release. Conversely, tryptophan-induced CCK secretion
was unaffected by inhibition of T1R1 expression, in
agreement with tryptophan not being an agonist for
T1R1-T1R3(54).
Thus, both CaSR and T1R1-T1R3 have been recog-
nised as intestinal L-amino acid sensors mediating CCK
secretion in response to aromatic amino acids such as
L-phenylalanine(44,54). Using a range of agonists and
antagonists of CaSR and T1R1-T1R3, it has been
demonstrated that CaSR is an intestinal L-amino acid
receptor specifically sensing aromatic amino acids,
while T1R1-T1R3 responds to a broad spectrum of
L-amino acids provoking CCK secretion from intestinal
endocrine I-cells(54).
Peptone receptor
The identity of the cell surface receptor(s) involved in
peptone-induced CCK release remains unknown.
GPCR92/93 is not a member of the C-class GPCR but
has been proposed as a candidate sensor for peptones
in STC-1 cells(55). Further work is required to elucidate
the peptone-sensing role of this GPCR, if any, in the
intestine.
Fats
Fats play an important role in nutrition. As well as pro-
viding 30–40 % of total body energy, they also offer
essential fatty acids such as linoleic (n-6) and α-linoleic
(n-3) acid that cannot be de novo synthesised in the
body. Like other macronutrients, fats must first be
digested before triggering hormone secretion and are
much more effective when administered into the gut
lumen than into the circulation. Fat ingestion stimulates
the secretion of a number of gut hormones, including
CCK, GLP-1 and GIP(56). It is reported that long-chain
fatty acids inhibit gastric emptying and induce satiety(57),
with SCFA eliciting GLP-1 and PYY secretion(58).
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Intestinal fatty acid sensing
There are four principal GPCR, FFA1-FFA4, that have
been officially classified as members of a NEFA receptor
family. FFA1 (GPR40) and FFA4 (GPR120) are acti-
vated by both saturated and unsaturated medium-chain
(carbon length 8–12) and longer chain (carbon chain
length 14–22) fatty acids and are mainly Gαq-coupled
(59).
The supporting evidence that long-chain fatty acid recep-
tors contribute directly to intestinal fatty acid chemosen-
sing is from the findings that their expression in the GI
tract is largely limited to the EEC population. The pattern
of expression of FFA4 in EEC appears to be similar to
that of FFA1. This has highlighted the need for highly
selective ligands to probe their functions. A number of
preclinical and clinical development programmes have
explored the therapeutic potential of agonists of
FFA1(60,61). Indeed, some synthetic agonists of FFA1
have shown the capacity to improve glycaemic control
in diabetes(62). However, questions remain in terms of sus-
tainability of effects during long-term treatment. There are
conflicting experimental evidence relating to the roles of
FFA1 and FFA4 and is not clear which one plays a
more important role in enteroendocrine fatty acid sens-
ing(63). Despite such concerns, the evidence suggests
many positive reasons to promote FFA4 as a promising
therapeutic target. They include the potential capacity to
regulate GLP-1 secretion from L-cells to promote insulin
release and to reduce insulin resistance via anti-
inflammatory mechanisms. Thus, efforts have been
made in medicinal chemistry for improving the selectivity
of ligands between FFA1 and FFA4, and it is proposed
that perhaps combined agonists of FFA1 and FFA4
may impart greater anti-diabetic efficacy, than targeting
either receptor selectively(64).
The SCFA receptors FFA2 (GPR43) and FFA3
(GPR41) have been shown, by immunohistochemistry,
to be expressed in colonic L-cells. They selectively bind
to and are activated by SCFA (carbon chain length 1–
6), particularly acetate (C2), propionate (C3) and butyr-
ate (C4). FFA2 responds to C2–C3 fatty acids and cou-
ples to Gαi/o as well as Gαq, whereas FFA3
preferentially binds C3–C5 and couples only to Gαi/o.
These SCFA are generated predominantly in the distal
gut by microbial fermentation of non-digestible carbohy-
drates, such as fibre and NSP. It has been reported that
non-digestible and fermentable dietary fibre and starch,
as well as SCFA themselves, enhance GLP-1 secre-
tion(65). Moreover, the SCFA-induced release of GLP-1
from EEC appears to be mediated by FFA2(66).
Although also activated by the same group of SCFA
as FFA2, and with a broadly similar expression profile,
FFA3 is less well characterised than FFA2. To date,
there have been no reports of highly selective synthetic
ligands for FFA3 that target the same binding site as
SCFA, and as such, detailed understanding of the func-
tion of this receptor lags behind(67). There is also signifi-
cant species orthologue variation in the pharmacology of
SCFA receptors in respect to their endogenous ligands,
which can be translated to species selectivity of synthetic
ligands targeting these receptors.
As alterations in population and diversity of gut
microbiota are associated with dysbiosis, there is consid-
erable interest in both prebiotic and probiotic strategies
to modulate microbial populations and hence the effect-
iveness of SCFA production(68). Thus, the physiological
role of SCFA receptors, and their relative importance,
compared with other possible targets of prebiotic supple-
mentation remains to be established.
Other NEFA-related receptors
GPR84 is recognised as a receptor responsive to
medium-chain fatty acids. However, it is by far the
least studied and understood of the currently described
receptors for fatty acids. GPR119 is predominantly
coupled to Gαs and is responsive to monoacylglycerols,
products of TAG hydrolysis. It is proposed that small-
molecule ligands of GPR119 increase GLP-1, GIP and
insulin release(69), however studies have shown these
ligands have limited glucose lowering and incretin activ-
ity in subjects with type 2 diabetes(70).
Conclusion
The nutrient-sensing GPCR, expressed in EEC, play
important roles in sensing the gut luminal environment,
transmitting nutrient-evoked signals leading to coordin-
ation of various physiological functions such as nutrient
digestion, absorption, insulin secretion and food intake.
Targeting the gut-expressed sweet receptor,
T1R2-T1R3, with dietary sweetener additives has made
a significant contribution to veterinary medicine, through
enhancing absorption of glucose, electrolytes and water
(oral rehydration therapy) in young animals, thereby pre-
venting weaning-induced intestinal disorders. This strategy
may also have applications for the prevention of digestive
disorders in premature or newborn human infants. As
many GPCR are targets for numerous drugs used in clin-
ical practice, a number of GPCR expressed in gut chemo-
sensory cells are currently under assessment as potential
new pathways for treating diabetes and obesity.
However, a number of these receptors remain poorly or
incompletely characterised. It is envisaged that access to
high-quality and well-defined agonists/antagonists, appro-
priate animal models, closer collaborations between differ-
ent disciplines and true ligand selectivity/specificity will
allow further expansion of this GPCR repertoire. It is pre-
dicted that with these basic criteria in place, the potential
for much more convincing target validation of nutrient-
sensing GPCR will be possible.
With the major role that gut nutrient sensing plays in the
control of GI physiology and gut–brain communication, it
is expected that further therapeutic successes and nutritional
recommendations will arise from research in this area.
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